AVONELLE-X Trial Shows Stable Vision and Anatomy in nAMD Over 4 Years
Overview
The AVONELLE-X extension trial demonstrates that faricimab maintains stable best-corrected visual acuity (BCVA), retinal anatomy, and central subfield thickness in neovascular AMD patients over 3 to 4 years. Patients required fewer injections over time, with a median of about 7 injections in years 3 and 4, and more than 60% achieved dosing intervals up to 16 weeks.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss, typically managed with anti-VEGF therapies requiring frequent injections. Previous studies like TENAYA and LUCERNE established the efficacy and safety of faricimab, a dual-action agent targeting VEGF and Ang-2. AVONELLE-X is the largest extension trial to date, evaluating long-term outcomes and durability of faricimab treatment beyond 2 years.
Data Highlights
| Parameter | Baseline (Parent Trials) | End of Year 2 | End of Year 4 |
|---|---|---|---|
| Mean BCVA (letters) | ~61 | 65.8 | 63.8 |
| Median injections (years 3-4) | ~7 total | ||
| Patients with persistent retinal fluid (aflibercept Q8w at year 2) | 152 | ||
| Reduction in patients with fluid after switch to faricimab | 44% fewer at year 4 | ||
| Patients achieving 16-week dosing interval | >60% at years 3 and 4 | ||
| Patients maintaining 20/40 vision or better | 75% at year 4 | ||
Key Findings
- Faricimab treatment maintained stable BCVA with a slight decline from 65.8 letters at year 2 to 63.8 letters at year 4.
- Median number of injections decreased to approximately 7 over years 3 and 4, indicating increased durability.
- Over 60% of patients achieved extended dosing intervals up to 16 weeks by years 3 and 4.
- Switching from aflibercept to faricimab reduced persistent retinal fluid by 44% in difficult-to-treat patients.
- 75% of patients who started with 20/40 vision maintained this level or better after 4 years of treatment.
- Faricimab demonstrated a consistent and favorable safety profile with no cases of occlusive vasculitis reported in the extension trial.
Clinical Implications
These findings suggest faricimab offers a durable treatment option for nAMD, enabling extended dosing intervals and potentially reducing treatment burden. Maintaining stable vision and anatomy over 4 years supports its use in long-term management, especially for patients with persistent fluid on other anti-VEGF agents. Clinicians may consider switching to faricimab to improve anatomical outcomes and sustain visual acuity with fewer injections.
Conclusion
The AVONELLE-X trial confirms that faricimab provides sustained visual and anatomical stability in nAMD patients over 4 years with a favorable safety profile and reduced injection frequency. This supports its role as a long-term, durable therapy bridging the gap between clinical trial efficacy and real-world treatment challenges.
References
- Sheth V.S. & Singer M.A. 2024 -- AVONELLE-X Findings: Stable Vision, Anatomy, and Thickness in nAMD
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
